Jump to content

COVID News and Commentary


Schmidt Meister
 Share

Recommended Posts

New Pfizer Data Reveal Horrifying Rates of Miscarriage

"Since the rollout of the experimental COVID shots, U.S. health officials have adamantly claimed the shots are safe for pregnant women and their unborn babies

 Meanwhile, now-released Pfizer court-ordered, released data — which the Food and Drug Administration wanted to hide for 75 years — reveal the miscarriage rate among women whose pregnancy outcomes were known was 87.5%. The true rate may be higher or lower, as Pfizer did not record or report pregnancy outcomes for 238 of the 274 women known to be pregnant during the trial"

https://www.technocracy.news/war-zone-new-pfizer-data-reveal-horrifying-rates-of-miscarriage/

Birth Rates Are Suddenly Plummeting Worldwide

"For example, Germany recently released data showing a 10% decline in birth rate during the first quarter of 2022.

The live birth rate graph for Sweden looks much the same, with a 14% drop.

Between January and April 2022, Switzerland’s birth rate was 15% lower than expected, the U.K.’s was down by 10% and Taiwan’s was down 23%.20,21,22 In Hungary, MP Dúró Dóra has expressed concern about a 20% drop in birth rate during January 2022, compared to January 2021.23

The U.S. is also showing signs of a drop in live births. Provisional data from North Dakota show a 10% decline in February 2022, 13% reduction in March and an 11% reduction in April, compared to the corresponding months in 2021.24"

  • Like 1
  • Sad 2
Link to comment
Share on other sites

On 8/29/2022 at 8:18 AM, pipedreams said:

1d522d8e87fdcd02.jpeg

It doesn't matter. The vaxxed and boosted (well, their families) that die from the disease, that is seemingly barely noticeable among the unvaxxed at this point, will sing the praises. You know, it could have been so much worse. Just like they are told.

Da Boy is recovering from his second torn rotator cuff in 2 years, and is having a second neck surgery. Never had allergies or malaise before either. At 40 he was doing PT with the Para Rescue platoon. He has had fits since that first jab. 42 now and trying to decide if he wants to do 4 extra years to increase his retirement percentage. It was a no brainier for him 18 months ago.

  • Like 3
  • Sad 1
Link to comment
Share on other sites

image.png.586705e524f09cc0283e0da6c6ddd41c.pnghttps://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects?email_share=true&expedited_modal=true

https://creativedestructionmedia.com/news/2022/09/02/ivermectin-reduces-mortality-rate-from-covid-19-by-92-with-regular-use/

Lots to read if interested:

Abstract

Background

We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect.

Methods

This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates.

Results

Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001). The infection rate was 32% lower for irregular users than non-users (RR: 0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants, regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, between regular users and irregular users, and 1,542 subjects between non-users and irregular users. The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was 92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower than irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while irregular users had a 51% reduction compared to non-users (RR: 0.49; 95% CI: 0.32-0.76; p = 0.001).

Conclusion

Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.

  • Like 2
  • Thanks 1
Link to comment
Share on other sites

1 hour ago, pipedreams said:

image.png.586705e524f09cc0283e0da6c6ddd41c.pnghttps://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects?email_share=true&expedited_modal=true

https://creativedestructionmedia.com/news/2022/09/02/ivermectin-reduces-mortality-rate-from-covid-19-by-92-with-regular-use/

Lots to read if interested:

Abstract

Background

We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect.

Methods

This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates.

Results

Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001). The infection rate was 32% lower for irregular users than non-users (RR: 0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants, regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, between regular users and irregular users, and 1,542 subjects between non-users and irregular users. The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was 92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower than irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while irregular users had a 51% reduction compared to non-users (RR: 0.49; 95% CI: 0.32-0.76; p = 0.001).

Conclusion

Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.

Image - Ain't nobody got time for that.gif - Glee TV Show Wiki - Wikia

  • Like 1
  • Haha 1
Link to comment
Share on other sites

12 hours ago, railfancwb said:

Ad in local weekly paper. Have seen it in more than one issue recently. 

09DCF409-1405-4116-8E4F-1B623AFDF2EA.jpeg

Local radio stations are playing a "Get Vaccinated" Commercial once or twice an hour. Local TV stations are doing so more.

They are dancing around the requirement to list top side effects for drug advertisements., Very carefully not mentioning the drug name, just the manufacturer.

 

  • Like 3
Link to comment
Share on other sites

1 hour ago, pipedreams said:

They sure are advertising it hard. The "accepted" oral treatment as well. Funny how they are VERY careful not to mention a drug name. They would have to disclose side effects, and ain't no body got time for that, huh?

I don't wish the four largest pharmaceutical companies to go belly up, that would be tragic, but would sure like some pain, suffering, and rethinking of their motivation and morality.

It seems they are blaming everything but an over manufactured panic and over manufacturing. Just two companies and over a dose for every single human on earth, per year. Seriously? You wonder why you have to dump the nightmare?

  • Thanks 4
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share

  • Please Donate To TBS

    Please donate to TBS.
    Your support is needed and it is greatly appreciated.
×
×
  • Create New...